Loading
A phase 2 trial of Abexinostat in non-Hodgkin lymphoma, run by Xynomic Pharmaceuticals, Inc., active and no longer recruiting.
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma is a phase 2 interventional study registered as NCT03934567 by Xynomic Pharmaceuticals, Inc., with 87 participants enrolled, started 2020-04-22 and due to reach its primary completion in 2025-01-29. Interventions recorded: Abexinostat.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xynomic Pharmaceuticals, Abexinostat, Follicular lymphoma.
Shares Xynomic Pharmaceuticals, Abexinostat, Non-Hodgkin lymphoma (all types).
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Xynomic Pharmaceuticals, Abexinostat.
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Follicular lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/